Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis

The use of rituximab (RTX), an anti-CD20 monoclonal antibody (Ab), in refractory myasthenia gravis (MG) is associated with a better response in patients with Abs to the muscle-specific tyrosine kinase (MuSK) than in other MG subgroups. Anti-MuSK Abs are mostly IgG4 with proven pathogenicity and posi...

Descripción completa

Detalles Bibliográficos
Autores principales: Marino, Mariapaola, Basile, Umberto, Spagni, Gregorio, Napodano, Cecilia, Iorio, Raffaele, Gulli, Francesca, Todi, Laura, Provenzano, Carlo, Bartoccioni, Emanuela, Evoli, Amelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214629/
https://www.ncbi.nlm.nih.gov/pubmed/32431692
http://dx.doi.org/10.3389/fimmu.2020.00613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214629/
https://www.ncbi.nlm.nih.gov/pubmed/32431692
http://dx.doi.org/10.3389/fimmu.2020.00613

Ejemplares similares